Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 14/20 | 0.50 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537723 | 1.00 | FASN (0.50) | FASNBACE1CTSDBRD4CREBBP | |
| SCHEMBL7544375 | 0.95 | BACE1 (0.53) | FASNBACE1CTSDBRD4CREBBP | |
| SCHEMBL7546538 | 0.92 | BACE1 (0.48) | FASNBACE1CTSDBRD4CREBBP | |
| SCHEMBL2969191 | 0.90 | FASN (0.47) | FASNBACE1CTSD | |
| SCHEMBL8199131 | 0.90 | FASN (0.47) | FASNBACE1CTSD | |
| SCHEMBL2969188 | 0.90 | FASN (0.47) | FASNBACE1CTSD | |
| SCHEMBL12173774 | 0.90 | FASN (0.47) | FASNBACE1CTSD | |
| SCHEMBL12496331 | 0.90 | FASN (0.39) | FASNBACE1CTSDBRD4 | |
| SCHEMBL2967070 | 0.89 | FASN (0.57) | FASN | |
| SCHEMBL2967073 | 0.89 | FASN (0.57) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | FASN 3111/4885BACE1 8/4885CTSD 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.